Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. EVMN
EVMN logo

EVMN News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

EVMN News

Evommune Shares Plunge 38% After Drug Trial Failure

5d agoNewsfilter

Evommune Executives Under Investigation for Insider Trading Ahead of Drug Trial Failure

5d agoPRnewswire

Evommune Shares Drop 31% After Phase 2b Trial Misses Primary Endpoint

6d agoseekingalpha

Evommune Reports Phase 2b Trial Results for EVO756

6d agoNASDAQ.COM

Evommune's Clinical Trial Fails to Meet Primary Endpoint

6d agoNewsfilter

Evommune, Inc. Reports Q1 Financial Results

May 08 2026seekingalpha

Evommune Showcases Expansion Opportunity for EVO756 in Migraine Prophylaxis

Apr 06 2026Newsfilter

Evommune Biotech Stock Shows Huge Potential

Mar 10 2026Fool

EVMN Events

06/29 16:30
Major Averages Finish Broadly Higher as Investors Await Middle East News
The major averages finished broadly higher as investors await news out of the Middle East. President Trump said the U.S. and Iran will meet to negotiate after days of strikes as the market shifts focus from geopolitics back toward macro data. Investors are watching labor market releases, including the JOLTS report and Thursday's payroll report, for clues on the Federal Reserve path. Markets continue to weigh a resilient economy against concerns that sticky inflation could keep the Fed more restrictive than expected.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:SpaceXwillon July 7Comcastplans to separate intothrough a tax-free spin-off of NBCUniversal and SkySpaceXand Charterhave discussed partnering on a mobile phone offering,Verizonand BT Groupwilland combine international operationsRocket LabIridiumfor $54 per share in a cash and stock transaction2. WALL STREET CALLS:Robloxto Buy at AreteAdobeto Neutral at Phillip SecuritiesDoximityto Underperform from Buy at BofAQuantinuumwith mostly Buy or equivalent ratings as Wall Street rolled out coverageCoverage of Liftoff Mobilewas alsowith mostly bullish ratings3. AROUND THE WEB:Carlislehas made unsolicited offers for Owens Corning, WSJ reportsEli Lillyand Regeneronare among the first selections for the FDA's PreCheck program, CNBC reportsAmazoncould pay more for Anthropic's technology, The Information reportsIntelis gaining momentum from the AI boom and new partnerships with Nvidia, Apple, and Elon Musk's Terafab project, but its long-term future depends on proving its new 14A manufacturing process can succeed and help restore U.S. chip production, New York Times reportsSamsungand SK Hynix intend to invest over $500B in a new chip-making hub in South Korea, WSJ says4. MOVERS:Repay Holdingsincreases after Forager Fundthe company for $5.25 per shareFuelCellgains after B. Rileythe stock to BuyPalisade Biohigher afterto start its ulcerative colitis studyEvommunelower after Phase 2b trial of EVO756Larimar Therapeuticsfalls afterof its rolling BLA for nomlabofusp5. EARNINGS/GUIDANCE:GameStopprovidedPerfect Moment, with EPS and revenue higher year-over-yearKolibri Global EnergyprovidedNiketoon June 30Constellation Brandstoon June 30INDEXES:The Dow rose 306.63, or 0.59%, to 52,182.74, the Nasdaq gained 522.53, or 2.07%, to 25,820.15, and the S&P 500 advanced 86.41, or 1.18%, to 7,440.43.

EVMN Monitor News

Evommune's EVO756 Fails Phase 2b Trial for Chronic Urticaria

Jun 29 2026

Evommune Inc's EVO301 Trial Shows Promising Results

Feb 10 2026

EVMN Earnings Analysis

No Data

No Data

People Also Watch